Pay in 4 interest-free payments of $5.69 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Phase 2 trial (NEJM, 2023) The landmark Phase 2 trial, published in the New England Journal of Medicine, randomized 338 adults with obesity to receive weekly subcutaneous retatrutide at doses of 1 mg, 4 mg, 8 mg, or 12 mg, or placebo, for 48 weeks
doi: 10.1186/s12967-015-0409-0 38 BoonpipattanapongTChewatanakornkulS
Physicochemical characteristics of LR3-IGF1 protein inclusion bodies: electrophoretic [PMID: 11485445] Laboratory literature summary: Physicochemical characteristics of LR3-IGF1 protein inclusion bodies: electrophoretic mobility studies
May 13, 2025 - Annual D-SNP Model of Care Training - Required Providers who have at least one Jefferson Health Plans Medicare Advantage Special (D-SNP) member assigned to their practice must have at least one person on their staff who is involved in the care of our dual-eligible special needs plan (D-SNP) members complete our annual D-SNP model of care training module
How Semaglutide and Tirzepatide Work Differently Semaglutide is a selective GLP1 receptor agonist with a halflife of ~1 week, enabling onceweekly dosing
US$ 22.52
US$ 23.21
US$ 26.02
